Konan partners with Chart2020

Article

Konan Medical USA, Inc. recently announced it has entered into an exclusive agreement with Chart2020, a provider of visual acuity and ocular performance testing software. Konan will develop, market, and distribute Chart2020 globally.

Irvine, CA-Konan Medical USA, Inc. recently announced it has entered into an exclusive agreement with Chart2020, a provider of visual acuity and ocular performance testing software. Konan will develop, market, and distribute Chart2020 globally.

Chart2020 v5 is an vision testing software platform with a redesigned user experience that can be controlled with the Chart2020 Duo app for iPad. The iPad can also be used to administer a number of guided, self-scoring tests including ColorDx, Konan’s new color vision testing software.

Central to Chart2020’s innovative user experience are SmartDocks, which enable users to quickly and easily access test libraries, sequences, system settings and Konan Wizards, a suite of guided, self-scoring tests. Examples of Wizards include stereo acuity, contrast sensitivity and ColorDx color vision diagnostics. Additionally, Chart2020 features global Sloan compliant optotypes for non-Western languages including Japanese, Korean, Russian, and Arabic, as well as Konan Kids, an optotype designed for children and illiterate adults.

Recent Videos
Jennifer Li, MD, details a talk she gave alongside Melissa Barnett, OD, FAAO, FSLS, FBCLA, at CRU 2025 in Napa, California.
Deb Ristvedt, DO, details a handful of presentations on glaucoma she gave during CRU 2025 in Napa, California.
Cecelia Koetting, OD, FAAO, DipABO, weighs in on patient assessments, staining pattern insights, and diagnostic tips for patients who may have dry eye disease.
Melissa Barnett, OD, FAAO, FSLS, FBCLA, discusses keratoconus management, diagnosis, and other key insights at CRU 2025.
Cecelia Koetting, OD, FAAO, DipABO, details a talk she gave among optometrists and ophthalmologists at CRU 2025.
Alongside Rachelle Lin, OD, MS, FAAO; Nguyễn, MD, MSc, detailed what treatments are currently available for retinal vascular diseases, including neovascular age-related macular degeneration and diabetic retinopathy.
Dr Paul Karpecki discusses atropine formulation from Sydnexis following NDA acceptance by FDA
Ali Tafreshi sits down with Optometry Times to discuss Topcon's "Healthcare from the Eye" initiative.
Nora Lee Cothran, OD, FAAO, details a real-world study that found IOP-lowering benefits when switching patients with glaucoma to latanoprostene bunod treatment.
OptiLIFT in action: Dr. Julie McLaughlin's experience with the new device
© 2025 MJH Life Sciences

All rights reserved.